Defunct Company
Total Trials
10
As Lead Sponsor
5
As Collaborator
Total Enrollment
1,049
NCT00715676
Phase 2 Safety and Efficacy Study of a Vitamin D Compound (DP001) in Postmenopausal Women With Low Bone Mineral Density
Phase: Phase 2
Role: Lead Sponsor
Start: Mar 31, 2007
Completion: Jan 31, 2009
NCT00625326
Study of Dose-Effect of COL-121 Ointment in Patients With Plaque-Type Psoriasis
Start: Jan 31, 2008
Completion: Jun 30, 2009
NCT01653379
A Phase 2A Dose-ranging and Pharmacokinetic Study of an Oral Vitamin D Compound (DP001) in Secondary Hyperparathyroidism
Start: Aug 31, 2012
Completion: Jul 31, 2014
NCT01922843
A Phase 2 Study of an Oral Vitamin D Compound (DP001) in Secondary Hyperparathyroidism in Patients on Hemodialysis
Start: Sep 30, 2013
Completion: Jun 30, 2014
NCT04466891
A Study of ZW25 (Zanidatamab) in Subjects With Advanced or Metastatic HER2-Amplified Biliary Tract Cancers
Role: Collaborator
Start: Oct 1, 2020
Completion: Jul 11, 2024
NCT05126433
Lurbinectedin Monotherapy in Participants With Advanced or Metastatic Solid Tumors
Start: Mar 3, 2022
Completion: Dec 20, 2023
NCT06695845
A Phase 2 Study of Zanidatamab in Patients With HER2-expressing Tumors
Start: Jan 14, 2025
Completion: Dec 31, 2027
NCT06961266
A Study to Investigate Efficacy, Safety, Tolerability, and Pharmacokinetics of JZP441 Compared With Placebo in Participants With Narcolepsy Type 1
Phase: Phase 1
Start: May 13, 2025
Completion: Apr 1, 2026
NCT07102381
A Phase 2 Neoadjuvant Study of Zanidatamab in Combination With Chemotherapy in Participants With HER2-positive Breast Cancer
Start: Sep 24, 2025
Completion: Aug 1, 2030